Nutraplus India Shuts Down Operations Following Asset Auction

Nutraplus India Ltd. has reported its financial results for the quarter ended June 30, 2024, revealing a complete halt in its business activities.

Financial Performance Update

For the first quarter of fiscal year 2025, Nutraplus India recorded zero standalone total revenue, a 100% decrease compared to ₹0.10 lakhs in the same period last year. The company also reported a net loss of ₹(0.39) lakhs for the quarter, with its earnings per share (EPS) at ₹(0.00).

For the full fiscal year ended March 31, 2024, the company's standalone revenue was ₹0.10 lakhs against total expenses of ₹6.26 lakhs, leading to a net loss of ₹(6.16) lakhs.

Business Operations Effectively Closed

The absence of any revenue signals a complete shutdown of business operations. This situation follows the auctioning of all the company's property, plant, and equipment under the SARFAESI Act, 2002. With no operational assets remaining, the company is unable to conduct any business.

Company's Troubled History

Nutraplus India Ltd., founded in 1990 as a maker of APIs and specialty chemicals, has faced sustained financial and regulatory challenges. The company was declared a Non-Performing Asset (NPA) in FY 2019-20, which ultimately led to the seizure and auction of its assets.

Auditors have repeatedly issued qualified reports, citing the company's failure to provide necessary financial data, making a full review difficult. The company has also missed SEBI's mandated deadlines for submitting financial results and audit reports.

Implications and Investor Outlook

With no physical assets and operations completely halted, a turnaround for Nutraplus India appears highly improbable. Investors face a significant risk of near-total loss on their investment due to the depletion of assets and looming insolvency.

Key Risks Ahead

Several risks loom for the company:

• The continued lack of operations and physical assets.
• Potential liquidation proceedings if liabilities cannot be settled.
• Further regulatory actions for non-compliance with disclosure rules.
• Auditors' qualified opinions, which highlight significant data unavailability and raise doubts about the company's ability to continue operating.

Industry Contrast

While Nutraplus India faces this critical state, other companies in the pharmaceutical sector, such as Venus Remedies Ltd., continue to operate and navigate market conditions, highlighting a clear difference in financial health.

What to Watch Next

Investors and observers should monitor:

• Any further regulatory filings or orders concerning liquidation or insolvency.
• Updates on the company's outstanding liabilities and creditor actions.
• Potential delisting proceedings by the stock exchange, given the cessation of business and assets.